Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MK-8690-002 | Other Identifier | MSD | |
| U1111-1326-7763 | Registry Identifier | UTN | |
| 2025-523479-49-00 | Registry Identifier | EU CT |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this protocol is to evaluate the efficacy of MK-8690 in participants with moderately to severely active ulcerative colitis. The primary hypothesis is that MK-8690 is superior to placebo with respect to the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Period 1: MK-8690 | Experimental | Participants will receive MK-8690 via subcutaneous injection for 12 weeks. |
|
| Period 1: Placebo | Placebo Comparator | Participants will receive placebo via subcutaneous injection for 12 weeks. |
|
| Period 2: MK-8690 | Experimental | Participants who do not respond to treatment in Period 1 (regardless of treatment assignment in Period 1) will receive MK-8690 via subcutaneous injection for 12 weeks. |
|
| Period 3: MK-8690 | Experimental | Participants who respond to treatment in either Period 1 or Period 2 will receive additional MK-8690 via subcutaneous injection for up to approximately 42 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MK-8690 | Drug | Solution for subcutaneous injection |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Achieving Clinical Remission Per Modified Mayo Score (MMS) at Week 12 | The MMS is a composite score of UC disease activity on a scale of increasing severity from 0-9, calculated by summing three subscores: Endoscopic subscore (ES), scored on a scale of increasing severity from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration); Stool frequency subscore (SFS), scored on a scale of increasing frequency from 0 (normal number of stools) to 3 (≥5 stools more than normal per day for the participant); and rectal bleeding subscore (RBS), scored on a scale of increasing severity from 0 (no blood seen) to 3 (blood alone passed). Clinical Remission is defined as an ES of 0 or 1 with no friability, RBS of 0, and SFS of 0 or 1 and not greater than the baseline SFS. | Week 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With One or More Adverse Events (AEs) | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experience an AE will be reported. |
Not provided
The main inclusion criteria include but are not limited to the following:
The main exclusion criteria include but are not limited to the following:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Toll Free Number | Contact | 1-888-577-8839 | Trialsites@msd.com |
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Merck Sharp & Dohme LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinnova Research ( Site 1042) | Recruiting | Anaheim | California | 92805 | United States |
Not provided
| Label | URL |
|---|---|
| Merck Clinical Trials Information | View source |
| Plain Language Summary | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Participants in Period 1 will have parallel assignment.
Not provided
Not provided
Period 1 is double-blind. Period 2 and Period 3 are open-label.
| Placebo | Other | Solution for subcutaneous injection |
|
| Up to approximately 12 months |
| Percentage of Participants Who Discontinued Study Intervention Due to an AE | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinue study treatment due to an AE will be reported. | Up to approximately 12 months |
| Percentage of Participants Achieving Clinical Response Per MMS at Week 12 | The MMS is a composite score of UC disease activity on a scale of increasing severity from 0-9, calculated by summing three subscores: ES, scored on a scale of increasing severity from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration); SFS, scored on a scale of increasing frequency from 0 (normal number of stools) to 3 (≥5 stools more than normal per day for the participant); and RBS, scored on a scale of increasing severity from 0 (no blood seen) to 3 (blood alone passed). Clinical response is defined as an MMS reduction of 2 or more points and 30% or more from baseline, plus a reduction of 1 or more points in RBS or an absolute RBS of 0 or 1. | Week 12 |
| Percentage of Participants With Endoscopic Improvement at Week 12 | Endoscopic improvement is defined as ES of 0 or 1 with no friability. The ES measures UC severity based on endoscopy on a 0-3 scale of increasing severity. | Week 12 |
| Percentage of Participants Achieving Clinical Remission Per Partial Modified Mayo Score (pMMS) at Week 12 | pMMS is a composite score of UC disease activity on a scale of increasing severity from 0-6, calculated by summing two subscores: SFS, scored from 0 (normal number of stools) to 3 (≥5 stools more than normal per day for the participant) and RBS, scored from 0 (no blood seen) to 3 (blood alone passed). Clinical remission per pMMS is defined as an RBS of 0 and SFS of less than or equal to 1. | Week 12 |
| Percentage of Participants Achieving Histologic-Endoscopic Mucosal Improvement (HEMI) at Week 12 | HEMI is defined as a Geboes score of 3.1 or less and ES of 0 or 1 with no friability. The Geboes score is a histologic grading system for inflammation in UC with scores ranging from 0 to 5.4, with higher scores indicating more severe inflammation. ES measures UC severity based on endoscopy, scored from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration). | Week 12 |
| Peak Gastroenterology Associates ( Site 1052) | Recruiting | Colorado Springs | Colorado | 80907 | United States |
|
| South Denver Gastroenterology, PC ( Site 1068) | Recruiting | Englewood | Colorado | 80113 | United States |
|
| Nature Coast Clinical Research ( Site 1045) | Recruiting | Inverness | Florida | 34452 | United States |
|
| Research Associates of South Florida - Miami - Southwest 8th Street ( Site 1072) | Recruiting | Miami | Florida | 33134 | United States |
|
| Gastroenterology Associates of Central Georgia ( Site 1060) | Recruiting | Macon | Georgia | 31201 | United States |
|
| University of Kansas Medical Center ( Site 1077) | Recruiting | Kansas City | Kansas | 66160 | United States |
|
| Tulane University School of Medicine ( Site 1073) | Recruiting | New Orleans | Louisiana | 70112 | United States |
|
| BVL Research - Kansas ( Site 1054) | Recruiting | Liberty | Missouri | 64068 | United States |
|
| Radboudumc ( Site 1650) | Recruiting | Nijmegen | Gelderland | 6525 GA | Netherlands |
|
| Wonju Severance Christian Hospital ( Site 1602) | Recruiting | Wŏnju | Kang-won-do | 26426 | South Korea |
|
| Kangbuk Samsung Hospital ( Site 1601) | Recruiting | Seoul | 03181 | South Korea |
|
| ID | Term |
|---|---|
| D003093 | Colitis, Ulcerative |
| ID | Term |
|---|---|
| D003092 | Colitis |
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D015212 | Inflammatory Bowel Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
Not provided
Not provided